Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer / Efecto de la baja expresión de HER2 sobre la eficacia neoadyuvante en el cáncer de mama operable
Clin. transl. oncol. (Print)
; 26(4): 880-890, Abr. 2024. graf
Article
em En
| IBECS
| ID: ibc-VR-51
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Objective: To investigate the effects of HER2-low expression (HER2-low) and HER2-zero expression (HER2-0) on the pathological complete response (pCR) rate and survival of patients following neoadjuvant chemotherapy. Methods: Eighty-six patients were followed up. Patients were divided into HER2-0 (immunohistochemistry (IHC) score of 0 (IHC0)) and HER2-low (IHC1+ or IHC2+/in situ hybridization non-amplified (ISH-)) groups according to the IHC detection of puncture tissues. After neoadjuvant chemotherapy, the clinical characteristics, pCR rate and DFS were compared between the two groups. Results: There were 24 (27.9%) cases with HER2-0 and 62 (72.1%) cases with HER2-low. Hormone receptor-positive (HR+) patients accounted for 77.4% of the HER2-low group, which was higher than 70.8% in the HER2-0 group, and there was no significant difference between the two groups (p = 0.524). There were statistical differences in the pT and pN stages between HER2-low and HER2-0 subgroups in the triple-negative breast cancer (TNBC) group after neoadjuvant chemotherapy. The HER2-low subgroup had an earlier T stage (p = 0.009), and the ratio of N0 to N1 in the HER2-low and HER2-0 subgroups was 92.9% and 71.4%, respectively (p = 0.037). The Ki-67 index and median PR value were significantly lower in the HER2-low group after neoadjuvant chemotherapy (p = 0.002, p = 0.018). The HER2 IHC score was altered in the HER2-low group, and the HER-2 (2+) score changed significantly (p = 0.002). Seventy-eight patients with complete immunohistochemical data were analyzed. The discordance rate of the IHC score of HER2 after neoadjuvant chemotherapy was 38.5%, and eight patients with HER2-low showed HER2-0 status, with a discordance rate of 10.3%. After neoadjuvant chemotherapy, The pCR rate was significantly lower in the HER2-low group compared with that in the HER2-0 group (4.8% vs. 8.3%; p = 0.914), but the recurrence and metastasis rates were lower in the HER2-low group...(AU)
Palavras-chave
Buscar no Google
Texto completo:
1
Coleções:
06-national
/
ES
Base de dados:
IBECS
Assunto principal:
Infecções por Coronavirus
/
Pandemias
/
Pediatria
/
Isolamento Social
/
Saúde da Criança
/
Dor
/
Apendicectomia
/
Doses de Radiação
/
Sêmen
/
Esportes
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Evaluation_studies
/
Guideline
/
Health_economic_evaluation
/
Incidence_studies
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
Aspecto:
Determinantes_sociais_saude
/
Ethics
Limite:
Humans
/
Male
/
Female
/
Child
/
Aged
/
Adult
/
Newborn
País/Região como assunto:
Europa
Idioma:
Es
/
En
Revista:
An. pediatr. (2003. Ed. impr.)
/
Cir. pediátr
/
Clin. transl. oncol. (Print)
/
Enferm. intensiva (Ed. impr.)
/
Int. microbiol
/
Med. oral patol. oral cir. bucal (Internet)
/
Nutr. clín. diet. hosp
/
Nutr. hosp
/
Radiología (Madr., Ed. impr.)
/
Reumatol. clín. (Barc.)
Ano de publicação:
2022
/
2023
/
2021
/
2024
Tipo de documento:
Article